Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 194

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors

Open access
Chatterjee, Samit, Lesniak, Wojciech G., Gabrielson, Matthew, Lisok, Ala, Wharram, Bryan, Sysa-Shah, Polina, Azad, Babak Behnam, Pomper, Martin G., Nimmagadda, Sridhar · 2016 · Oncotarget

Abstract

// Samit Chatterjee 1,* , Wojciech G. Lesniak 1,* , Matthew Gabrielson 1 , Ala Lisok 1 , Bryan Wharram 1 , Polina Sysa-Shah 1 , Babak Behnam Azad 1 , Martin G. Pomper 1,2 and Sridhar Nimmagadda 1,2 1 Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, MD, USA 2 Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA * These authors have contributed equally to this work Correspondence to: Sridhar Nimmagadda, email: // Keywords : MPDL3280A, immunotherapy, immune escape, molecular imaging, personalized medicine Received : January 02, 2016 Accepted : January 16, 2016 Published : February 02, 2016 Abstract Antibodies targeting the PD-1/PD-L1 immune checkpoint lead to tumor regression and improved survival in several cancers. PD-L1 expression in tumors may be predictive of response to checkpoint blockade therapy. Because tissue samples might not always be available to guide therapy, we developed and evaluated a humanized antibody for non-invasive imaging of PD-L1 expression in tumors. Radiolabeled [ 111 In]PD-L1-mAb and near-infrared dye conjugated NIR-PD-L1-mAb imaging agents were developed using the mouse and human cross-reactive PD-L1 antibody MPDL3280A. We tested specificity of [ 111 In]PD-L1-mAb and NIR-PD-L1-mAb in cell lines and in tumors with varying levels of PD-L1 expression. We performed SPECT/CT imaging, biodistribution and blocking studies in NSG mice bearing tumors with constitutive PD-L1 expression (CHO-PDL1) and in controls (CHO). Results were confirmed in triple negative breast cancer (TNBC) (MDAMB231 and SUM149) and non-small cell lung cancer (NSCLC) (H2444 and H1155) xenografts with varying levels of PD-L1 expression. There was specific binding of [ 111 In]PD-L1-mAb and NIR-PD-L1-mAb to tumor cells in vitro , correlating with PD-L1 expression levels. In mice bearing subcutaneous and orthotopic tumors, there was specific and persistent high accumulation of signal intensity in PD-L1 positive tumors (CHO-PDL1, MDAMB231, H2444) but not in controls. These results demonstrate that [ 111 In]PD-L1-mAb and NIR-PD-L1-mAb can detect graded levels of PD-L1 expression in human tumor xenografts in vivo . As a humanized antibody, these findings suggest clinical translation of radiolabeled versions of MPDL3280A for imaging. Specificity of NIR-PD-L1-mAb indicates the potential for optical imaging of PD-L1 expression in tumors in relevant pre-clinical as well as clinical settings.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.7143

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 194

Metadata

Authors
Chatterjee, S., Lesniak, W. G., Gabrielson, M., Lisok, A., Wharram, B., Sysa-Shah, P., Azad, B. B., Pomper, M. G., & Nimmagadda, S.
Venue
Oncotarget
Published
2016-02-01
Volume
7
Issue
9
Pages
10215-10227
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2290610287
Cited by
194
References
9
FWCI
19.18
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.